🇺🇸 FDA
Patent

US 9873718

Structure-based peptide inhibitors of P53 aggregation as a new approach to cancer therapeutics

granted A61KA61K38/00A61P

Quick answer

US patent 9873718 (Structure-based peptide inhibitors of P53 aggregation as a new approach to cancer therapeutics) held by The Regents of the University of California expires Mon Jan 18 2038 00:00:00 GMT+0000 (Coordinated Universal Time). Status: granted.

Key facts

Applicant
The Regents of the University of California
Grant date
Tue Jan 23 2018 00:00:00 GMT+0000 (Coordinated Universal Time)
Expiration
Mon Jan 18 2038 00:00:00 GMT+0000 (Coordinated Universal Time)
Claims
16
CPC classes
A61K, A61K38/00, A61P, A61P35/00, A61P43/00